Geneva, Switzerland, based European medical diagnostics leader Unilabs has completed the acquisition of Alpha Medical group from private equity firm Mid Europa Partners for an undisclosed amount. This follows the announcement of the agreement on February 9th, 2017.
Unilabs SubHolding AB (publ) (the “Issuer”) today announced that it has priced its offering of €250,000,000 aggregate principal amount of 5.75% senior notes due 2025 (the “Notes”). The offering is expected to close on May 5, 2017.
Geneva based Unilabs today announced that it has reached an agreement to acquire Alpha Medical, a leading medical diagnostics company serving customers in Slovakia and the Czech Republic, from private equity firm Mid Europa Partners for an undisclosed amount.
Unilabs and funds advised by Apax Partners LLP announce that the purchase by Apax IX of Unilabs shares from Nordic Capital Fund VI and Apax France VII is complete and has now closed following clearance by the European Commission under the EU Merger Regulation.
European medical diagnostics leader Unilabs today announced the departure of its CFO, Karl Erik Clausen. He will leave the company on May 8th, 2017. Philipp Manser has been appointed as his successor.
The joint owners of Switzerland-based Unilabs, private equity funds Apax Europe VI, Nordic Capital Fund VI (“Nordic Capital”) and Apax France VII, announced today that Nordic Capital and Apax Partners France, have accepted an offer from Apax IX, advised by Apax Partners LLP, for the acquisition of their respective stakes in Unilabs.
Unilabs SubHolding AB (publ) today announces that it has issued notices of conditional redemption for all of its outstanding €355,000,000 8.5% Senior Secured Notes due 2018 (the “Fixed Rate Notes”) and €130,000,000 Senior Secured Floating Rate Notes due 2018 (the “Floating Rate Notes”), and Unilabs MidHolding AB (publ) (each of Unilabs SubHolding AB (publ) and Unilabs MidHolding AB (publ), an “Issuer”) today announces that it has issued a notice of conditional redemption for all of its outstanding 12.0% / 13.0% Second Lien PIK Toggle Notes due 2019 (the “PIK Notes” and each of the PIK Notes, Fixed Rate Notes and Floating Rate Notes, the “Notes”), in each case outstanding on the applicable Redemption Date (as defined below).
Q2 results delivered increased organic growth in net sales of 4.2% CER (1.8% reported) and organic EBITDA growth up by 20.1% CER (17.3% reported) on a like for like basis. The combination of constant revenue growth and excellent results from the Cost Leadership Initiative contributed to the substantial growth of EBITDA margins. The 2016 guidance is confirmed.
Skaraborgs Hospital has chosen to extend the existing laboratory services agreement with Unilabs in Sweden. The agreement covers the complete laboratory medical service for clinical chemistry, microbiology, pathology, cytology and transfusion medicine. The three years extension applies from February 2020.
Unilabs, one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services, closed Q1 above expectations in a robust start to the new financial year and also confirms it is on track to deliver 2016 targets.
Unilabs, one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services, announced further robust growth today, reporting that for the quarter ending 31st December 2015, revenue was €180.1m, compared to €165.9m in Q4 2014. The results show a significant and positive organic sales growth of 5.0% (CER) leading to organic EBITDA growth vs Q4 2014 of 24.5% (CER). This marks the company’s 6th successive quarter of positive organic EBITDA growth and 5th with a double digit growth rate.
Unilabs Sweden is a key player to the EU project "SMARTDIAGNOS- Next Generation sepsis diagnosis technology", which provides rapid diagnostics and better conditions for treatment for patients with blood poisoning.
As reports of Zika virus infections continue to spread through the world, a test to diagnose the virus is now offered by Unilabs. Results are available within a 3 hours’ time-frame.
Unilabs announces new appointment for General Manager Laboratory North as of January 2016.
Unilabs, one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services, announced further growth today, reporting that for the quarter ending 30 September 2015, revenue was €152.8m, compared to €141.7m in Q3 2014. The results show a significant and positive organic sales growth of 4.5% (CER†) leading to EBITDA growth vs Q3 2014 of 12.9%. This marks the 5th successive quarter of revenue growth, EBITDA growth and cost savings.
Chris Tue starts as General Manager UK on the 2nd November 2015.
Unilabs has had a strong footprint in the UK through its two business units, Unilabs IHS and Unilabs York Bioanalytical Solutions and hopes to significantly grow under the management of Chris.
October is the Breast Cancer Awareness Month, which is an annual campaign to increase awareness of the disease.
At Unilabs, we have already launched few initiatives to raise awareness around breast cancer and increase participation in screening programs.
Unilabs announced further growth today, reporting that for the quarter ending 30 June 2015, revenue was €172.1m, compared to €153.5m in Q2 2014. The results show a significant and positive organic sales growth of 7.1% (CER†) leading to EBITDA growth vs Q2 2014 of 25.6%. This marks the 4th successive quarter of revenue growth, EBITDA growth and cost savings.
Unilabs has been fully responsible for women mammography screening for the region of Skane since 2009 and gets to renew the confidence of the Skåne region for another 5+2 years.
Unilabs, one of the leading players in the €70bn a year European medical diagnostic market1 announced today that for the quarter ending 31 March 2015, reported revenue was €167.6m, compared to €155.2m in Q1 2014. The results show a significant and positive organic sales growth of 5.5% (CER†) leading to EBITDA growth vs last year of 12.2%.
Alejandro Cuartero was appointed General Manager Spain on the 1st May 2015.
On the 9th of April, Unilabs, along with Group of private practitioners and companies, participated in laying the first stone for the Beaune private Health Cluster. Of all Private Health Clusters of the Dijon area, the Beaune project is the only one to be 100% privately funded.
As of the 1st of April, Andreas Gattiker has taken up the role of General Manager Switzerland. His appointment follows that of Patrice Ferrand who joined Unilabs on the 23rd of April as General Manager France.
On 2nd March 2015, Unilabs started the provision of a managed service to BMI Ross Hall hospital from an onsite laboratory.
Unilabs announces today that Raffi Asadorian, CFO since 2009 has notified the Company of his resignation effective September 30, 2014, to pursue other opportunities. Karl Erik Clausen will succeed Raffi as Unilabs’s new CFO.
Unilabs and BGI have signed a collaboration agreement.